GMAB Earnings Date: Nov 5, 2026 — Genmab A/S
NASDAQ · Healthcare · Biotechnology
Updated
When is GMAB's next earnings date?
Genmab A/S (GMAB) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026 at 11:00 AM ET (during market hours). The consensus estimate is EPS of $0.37 on revenue of $1.20B.
How did GMAB do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Genmab A/S posted EPS of $4.91 versus the $0.37 estimate, a beat of 1483.9%. Revenue was $1.16B against a $1.12B estimate. The stock's 1-day post-earnings move was +1.9%.
How much does GMAB stock move after earnings?
GMAB beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.5% (up or down) in the day after earnings.
About Genmab A/S
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 0.37 | 4.91 | +1483.87% | $1.16B | ✅ Beat | +1.95% | +7.38% | +17.60% |
| 2026-05-07 | Q1 2026 | 0.17 | 0.08 | -51.18% | $896.0M | ❌ Miss | -2.98% | -4.80% | -9.82% |
| 2026-02-17 | Q4 2025 | 0.44 | 0.05 | -88.64% | $1.06B | ❌ Miss | -0.10% | -2.53% | -12.22% |
| 2025-11-06 | Q3 2025 | 0.46 | 0.65 | +40.43% | $1.02B | ✅ Beat | -1.20% | +4.39% | +8.74% |
| 2025-08-07 | Q2 2025 | 0.36 | 0.54 | +50.56% | $925.0M | ✅ Beat | +5.49% | +5.39% | +28.03% |
| 2025-02-12 | Q4 2024 | 0.28 | 0.85 | +203.57% | $921.6M | ✅ Beat | +4.24% | +16.30% | +5.66% |
| 2024-11-06 | Q3 2024 | 0.35 | 0.29 | -17.14% | $816.0M | ❌ Miss | -1.85% | -1.23% | -3.96% |
| 2024-08-08 | Q2 2024 | 0.33 | 0.31 | -6.06% | $779.5M | ❌ Miss | +2.31% | +1.28% | +4.01% |
Showing last 8 quarters.